Article PDF
Avoid common mistakes on your manuscript.
References
Dunaif A., Givens J.R., Haseltine F., Merriam G.R. The polycystic Ovary Syndrome. Blackwell Scientific, Cambridge 1992.
Diamanti-Kandarakis E., Kouli Ch., Tsianateli Th., Zapanti E., Filandra F., Spina G., Bergiele A. A survey of PCOS in Greek population (metabolic and hormonal associations). Program of the 79th annual meeting of the Endocrine society Minneapolis, Minnesota, 1997 (Abstract 341).
Diamanti-Kandarakis E., Dunaif A. New perspectives in polycystic ovary syndrome. Trends Endocrinol. Metab. 7: 267, 1996.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18: 774, 1997.
Dunaif A., Futterweit W., Segal K.R., Dobransky A. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes 38: 1165, 1989.
Ovesen R., Moller J., Ingerselev H.J., Jorgensen J.O.L., Mengel A., Schmitz Q., Alberti K.G.M.M., Moler N. Normal basal and insulin-stimulated fuel metabolism in lean women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 77: 1636, 1993.
Toscano V., Bianchi P., Balducci R., Guglielmi R., Mangiantini A., Lubrano C., Sciarra F. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism. Clin. Endocrinol. 36: 197, 1992.
E. Diamanti-Kandarakis. The polycystic ovary syndrome: pathogenesis, metabolic implications, and therapeutic approach. Annals of the New York Academy of Sciences. Adolescent Gynecology and Endocrinology Basic and Clinical Aspects: 816: 177, 1997.
Velazquez E.M., Menoza S., Hamer T., Sosa F.&G., Lueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperan-drogenemia and systolic blood pressure, while facilitang normal menses and pregnancy. Metabolism 43: 647, 1994.
Diamanti-Kandarakis E., Mitrakou A., Hennes M.M.I., Platanissiotis D., Kaklas N., Spina J., Georgiadou E., Hoffmann R.G., Kissebah A.H., Raptis S. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 44: 525, 1995.
Diamanti-Kandarakis E., Kouli C., Tsianateli T., Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. J. Endocrinol. 138: 269, 1998.
Moghetti P., Tosi F., Castello R., Magnani C.M., Negri C., Brun E., Furlani L., Caputo M., Muggeo M. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: Evidence that androgens impair insulin action in women. J. Clin. Endocrinol. Metab. 81: 952, 1996.
DeLeo V., Lanzetta D., D’Antona D., LAMarka A., Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J. Clin. Endocriol. Metab. 83: 99, 1998.
Lobo R.A., Goebelsmann U., Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 57: 393, 1983.
Cusan L., Dupont A., Belanger A., Tremblay R.R., Manhes G., Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide. J. Am. Acad. Dermatol. 23: 462, 1990.
Diamanti-Kandarakis E., Tolis G., Duleba A. Androgens and therapeutic aspects of antiandrogens in women. J. Soc. Gynecol. Invest. 2: 577, 1995.
Gardiner P., Schrode K., Quinlan D., Martin B.K., Boreham D.R., Rogers M.S., Stubbs K., Smith M., Karim A. Spironolactone metabolism: Steady-state serum levels of the sulfur-containing metabolites. J. Clin. Pharmacol. 29: 342, 1989.
Schane H.P., Potts G.O. Oral progestational activity of spironolactine. J. Endocrinol. Metab. 47: 691, 1978.
Levy J., Burshell A., Marbach M., Afilalo L., Glick S.M. Interaction of spironolactone with oestradiol receptors in cytosol. J. Endocrinol. 84: 371, 1980.
Menard R.H., Guenthner T.M., Kon H., Gillette J.R. Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. J. Biol. Chem. 254: 1726, 1979.
Serafini P.C., Catelino J., Lobo R.A. The effect of spironolactone on genital skin 5 alpha-reductase activity. Steroid Biochem. 23: 191, 1985.
Shapiro G., Evron S. A novel use of spironolactone: Treatment of hirsutism. J. Clin. Endocrinol. Metab. 51: 429, 1980.
Dorrington Ward P., McCartney A.C., Holland S., Scully J., Carter G., Alaghband-Zadeh J., Wise P. The effect of spironolactone in hirsutism and female androgen metabolism. Clin. Endocrinol. (Oxf.) 23: 161, 1985.
Namer M. Clinical applications of antiandrogens. J. Steroid Biochem. 31: 719, 1988.
Messina M., Manieri C., Biffignandi P., Massucchetti C., Novi R.F., Molinatti G.M. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J. Endocrinol. Invest. 6: 23, 1983.
Cumming D.C., Yang J.C., Rebar R.W., Yen S.S. Treatment of hirsutism with spironolactone. JAMA 247: 1295, 1982.
Ames R.P., Hill P. Raised serum lipid concentrations during diuretic treatment of hypertension: A study of predictive indexes. Clin. Sci. Mol. Med. Suppl. 4: 3115, 1978.
Cusan L., Dupont A., Gomez J.-L., Tremblay R.R., Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil. Steril. 61: 28, 1994.
Milewicz A., Silber D., Kirschner M.A. Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet. Gynecol. 61: 429, 1983.
Nielsen P.G. Treatment of female acne vulgaris with a cream containing the antiandrogen canrenone. Dermatologica 166: 275, 1983.
Hammerstein J., Meckies J., Leo-Rossberg I., Moltz L., Zielske F. Use of cyproterone acetate (CPA) in the treatment of acne, hisrutism and virilism. J. Steroid. Biochem. 6: 827, 1975.
Belisle S., Love E.J. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results in a multicentered Canadian Study. Fertil. Steril. 46: 1015, 1986.
Neumann F., Topert M. Pharmagology of antiandrogens. J. Steroid Biochem. 25: 885, 1986.
Lobl T.J., Cambell J.A., Tindall D.J., Cunningham G.R. Androgen antagonists in androgen target issues. Pharmacol. Ther. 24: 367, 1984.
Eil C., Edelson S.K. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J. Clin. Endocrinol. Metab. 59: 51, 1984.
Humpel M., Wendt H., Schulze P.-E., Dogs G., Weiss C., Speck U. Bioavailability and pharmacokinetics of cyproteroneacetate after oral administration of 2.0 mg cyproterone acetate in combination with 50 µg ethinyloestradiol to 6 young women. Contraception 15: 579, 1977.
Eden J.A. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate. Med. J. Aust. 155: 677, 1991.
Golland I.M., Elstein M.E. Result of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann. NY Acad. Sci. 687: 263, 1993.
Greenwood R., Brummitt L., Burke B., Cunliffe W.J. Acne: Double blind clinical and laboratory trial of tetracycline, oestroge-cyproterone acetate, and combined treatment. Br. Med. J. (Clin. Res. Ed.) 291: 1231, 983.
Lachnit-Fixon U. The development and evaluation of an ovulation inhibitor (Diane) containing an antiandrogen. Acta Obstet. Gynecol. Scand. (Sweden) 58: 33, 1979.
Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of multicenter study. Acta Obstet. Gynecol. Scand. (Suppl.) 134: 29, 1986.
Wishart J.M. An open study of triphasyl and Diane 50 in the treatment of acne. Australias J. Dermatol. 32: 51, 1991.
Vermeulen A., Rubens R. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildy hirsute or acneic young women. Contraception 38: 419, 1988.
Stivel M.S., Kauli R., Kaufman H., Laron Z. Adrenocortical function in children with precocious sexual development during treatment with cyproterone acetate. Clin. Endocrinol. 16: 163, 1982.
Cusan L., Dupont A., Belanger A., Tremblay R.R., Manhes G., Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide. J. Am. Acad. Dermatol. 23: 462, 1990.
Brogden R., Chrisp P. Flutamide. Drugs Aging 1: 104, 1991.
Schulz M., Schmoldt A., Donn F., Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur. J. Pharmacol. 34: 633, 1988.
Diamanti E., Kaklas N., Georgiadou E., Spina J., Rangou D., Chlouverakis C. The impact of a pure antiandrogen on gonadotropin and prolactin secretion in women with PCO. Second International Capri Conference: Neuroendocrine and peripheral disorders of female reproductive system: Pathophysiologyandtherapies: May 22, Capri (Italy), 1992 Abstr. No 123.
Mowszowicz I., Wright F., Vincens M., Rigaud C., Nahoul K., Mavier P., Guillemant S., Kuttenn F., Mauvais-Jarvis P. Androgen metabolism in hirsute patients treated with cyproterone acetate. J. Steroid Biochem. 20: 757, 1984.
Diamanti E., Kaklas N., Spina J., Georgiadou E., Rangou D., Chlouverakis K. Intraovarian regulators and polycystic ovarian syndrome. The effect of and androgen receptor blocker on gonadotropin release and androgen levels in PCO. Satellite symposium of the 9th International Congress of Endocrinology, Abstr. No 79, 1992.
Kontula K.K., Seppanen P.J., van Duyne P., Bardin C.W., Janne O.A. Effect of a nonsteroidal antiandrogen, flutamide, on androgen receptor dynamics and ornithine decarboxylase gene expression in mouse kidney. Endocrinology 116: 226, 1985.
Balzano S., Cappa M., Migliari R., Scarpa R.M., Danielli E., Campus G., Pintus C., Sica V., Usai E., Martino E. The effect of flutamide and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. J. Endocrinol. Invest. 11: 693, 1988.
Diamanti-Kandarakis E., Mitrakou A., Raptis S., Tolis G., Duleba A. The effect of a pure antiandrogen receptor blocker, Flutamide, on the lipid profile in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83: 2699–2705, 1998.
Wysowski D.K., Freiman J.P., Tourtelot J.B., Horton M.L. Fatal and non-fatal hepatotoxicity associated with flutamide. Ann. Intern. Med. 118: 860, 1993.
Rosman A.S., Frissora-Rodeo C., Marshal A.T., Reiter B.P. Cholestatic hepatitis following flutamide. Dig. Dis. Sci. 38: 1756, 1993.
Group TM-FS. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. J. Androl. 12: 372, 1991.
Sciarra F., Toscano V., Concolino G., DiSilverio F. Antiandrogens: clinical applications. J. Steroid Biochem. Mol. Biol. (U.K) 37: 349, 1990.
Vigersky R.A., Mehlman I., Glass A.R., Smith C.E. Treatment of hirsute women with cimetidite. N. Engl. J. Med. 303: 1042, 1980.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Diamanti-Kandarakis, E. How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?. J Endocrinol Invest 21, 623–629 (1998). https://doi.org/10.1007/BF03350788
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350788